THY1 and neoplasm: We found that patients with HCC CD90 mRNA higher than 3.8 au had a shorter time to tumor recurrence compared to patients with lower CD90 with tumor recurrence mean (95% CI) of 15.4 (11.8–19.0) vs. 25.2 (12.6–37.7) months after surgery, respectively (p < 0.05).